Phosphatidylinositol 3-Kinase
"Phosphatidylinositol 3-Kinase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase that catalyzes the conversion of 1-phosphatidylinositol into 1-phosphatidylinositol 3-phosphate.
| Descriptor ID |
D058539
|
| MeSH Number(s) |
D08.811.913.696.620.500.100
|
| Concept/Terms |
Phosphatidylinositol 3-Kinase- Phosphatidylinositol 3-Kinase
- Phosphatidylinositol 3 Kinase
- 1-Phosphatidylinositol 3-Kinase
- 1 Phosphatidylinositol 3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinase".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinase".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinase" by people in this website by year, and whether "Phosphatidylinositol 3-Kinase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 4 | 6 | 10 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphatidylinositol 3-Kinase" by people in Profiles.
-
Diabetes and susceptibility to infections: Implication for COVID-19. Immunology. 2021 11; 164(3):467-475.
-
Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. Mol Cell. 2020 10 01; 80(1):164-174.e4.
-
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2019 10; 84(4):809-817.
-
MiR-126 affects femoral fracture healing in rats through PI3K/AKT signaling pathway. Panminerva Med. 2021 Mar; 63(1):89-90.
-
miR-802 inhibits the aggressive behaviors of non-small cell lung cancer cells by directly targeting FGFR1. Int J Oncol. 2019 Jun; 54(6):2211-2221.
-
MicroRNA-199a-3p and MicroRNA-199a-5p Take Part to a Redundant Network of Regulation of the NOS (NO Synthase)/NO Pathway in the Endothelium. Arterioscler Thromb Vasc Biol. 2018 10; 38(10):2345-2357.
-
Bcl-XL and Mcl-1 upregulation by calreticulin promotes apoptosis resistance of fibroblast-like synoviocytes via activation of PI3K/Akt and STAT3 pathways in rheumatoid arthritis. Clin Exp Rheumatol. 2018 Sep-Oct; 36(5):841-849.
-
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer. 2018 06; 96:6-16.
-
Differential expression of miRNAs are associated with the insulin signaling pathway in preeclampsia and gestational hypertension. Clin Exp Hypertens. 2018; 40(8):744-751.
-
MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer. 2018 02 06; 118(3):366-377.